-
CD34⁺ CD19⁻ CD22⁺ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
Bueno et al, Blood 2022
-
CAR T-Cells With Dual Targeting of CD19 and CD22 in Adult Patients With Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial
Spiegel et al, Nature Medicine 2021
-
Structural Details of Monoclonal Antibody M971 Recognition of the Membrane-Proximal Domain of CD22
Ereno-Orbea et al, J. Biol Chem 2021
-
Antigen-Independent Activation Enhances the Efficacy of 41BB Co-Stimulated CD22 CAR T-Cells
Singh et al, Nature Medicine 2021
-
CD22-Directed Car T-Cell Therapy Induces Complete Remissions in CD19-Directed Car–Refractory Large B-Cell Lymphoma
Baird et al, Blood 2021
Publications
CARGO is advancing a pipeline
of next-generation adoptive
CAR T-cell therapies for cancer
